Epitalon (Epithalon)
Synthetic tetrapeptide, based on the natural pineal gland extract "epithalamin"
Quick Answer
A short synthetic peptide developed to reproduce the proposed activity of epithalamin, a pineal-gland-derived extract studied primarily by Russian researchers (notably at the St. Petersburg Institute of Bioregulation and Gerontology) in the context of aging research.
Why People Are Interested
A long-running fixture of the longevity-research conversation, tied to genuinely interesting (if narrowly sourced) hypotheses about telomerase activity and circadian regulation — ideas that keep it in the conversation even though independent replication is limited.
What People Hope It May Do
Anti-aging and longevity benefits linked to its proposed effects on telomere biology and sleep/circadian regulation. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Telomere-length and cellular-aging research (mostly from the originating research group)
Circadian rhythm / melatonin regulation research
General longevity-research interest
How It May Work
Proposed to influence telomerase activity and circadian/pineal signaling (e.g., melatonin regulation) — these are research hypotheses from a specific, relatively insular research tradition, not broadly replicated, independently-confirmed mechanisms.
What Human Research Shows
Some human studies exist, primarily from the originating Russian research group, generally older, smaller, and not replicated by large independent international trials at a scale comparable to FDA-approval-track compounds. This should be described honestly as limited and not independently well-replicated, rather than presented as strong evidence.
What Preclinical Research Shows
Includes animal-model aging and longevity research from the same research tradition.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to Epitalon (Epithalon) is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving Epitalon (Epithalon), search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No comprehensive, independently-replicated human safety database exists publicly at the scale expected for consumer guidance.
Regulatory Status
Not FDA-approved. Not available as an approved drug in the US; sold in some other countries as a registered product under different regulatory regimes — regulatory status varies significantly by country and should be described precisely, not generalized.
Recent development (2026-09-10, re-verified directly against primary FDA sources): Epitalon was discussed at the FDA's Pharmacy Compounding Advisory Committee meeting on July 24, 2026, specifically for the nominated use of insomnia — confirmed directly from the official FDA meeting agenda page and the epitalon-specific FDA briefing document (fda.gov/media/193345/download). That briefing document's own "Conclusion and Recommendation" section states plainly that FDA staff's evaluation "weighs against epitalon (free base) or epitalon acetate being placed on that list" — i.e., FDA staff specifically recommended against including epitalon on the 503A Bulks List, based on physical/chemical characterization gaps and insufficient nonclinical/clinical data (confirmed directly, not inferred). The Pharmacy Compounding Advisory Committee itself then voted (tight margin) to recommend adding epitalon to the list anyway — a real, documented staff-vs-committee split, the same pattern confirmed for TB-500 from the same meeting. This is a nonbinding advisory recommendation only — the FDA has not added epitalon to that list, nothing about its US legal status has actually changed, and it remains not FDA-approved. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. The specific committee vote tally (reported as 7-5, one abstention) comes from trade-press coverage (NCPA/AJMC/RAPS), not a primary FDA-published tally — cite as corroborated-but-not-FDA-primary-confirmed if used. Full sourcing in This Week in Peptides.
What We Still Don't Know
Whether the originating research group's findings replicate independently at scale, and whether any telomere-related laboratory effects translate into meaningful outcomes for people.
Limitations of Evidence
Research concentrated in one originating group/tradition; limited independent replication; older studies with smaller sample sizes; internationally inconsistent regulatory framing that content must not blur into an implied US approval.
Keep Researching
- Search ClinicalTrials.gov for Epitalon (Epithalon)
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-09-10 — FDA meeting/indication/staff-recommendation details and both human-study citations independently re-verified directly against primary FDA sources and the already-cited peer-reviewed review.